Patent application number | Description | Published |
20100158875 | MUSCLE DERIVED CELLS FOR THE TREATMENT OF GASTRO-ESOPHAGEAL PATHOLOGIES AND METHODS OF MAKING AND USING THE SAME - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration of symptoms for gastro-esophageal pathologies like gastro-esophageal reflux. | 06-24-2010 |
20130158662 | Muscle Derived Cells For The Treatment Of Gastro-Esophageal Pathologies And Methods Of Making And Using The Same - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration of symptoms for gastro-esophageal pathologies like gastro-esophageal reflux. | 06-20-2013 |
Patent application number | Description | Published |
20110015695 | GASTROINTESTINAL ELECTRICAL STIMULATION FOR THE TREATMENT OF PANCREATITIS - A method of preventing acute pancreatitis comprising positioning stimulatory electrodes in the stomach of an individual in need thereof; and administering repetitive trains of short pulse gastrointestinal electrical stimulation effective for suppressing the inflammatory response in the pancreas is provided herein. The electrodes are placed by laproscopic, endoscopic or surgical means. The gastrointestinal stimulation activates vagal reflexes. The activation of the vagal reflexes is via the gastric and pancreatic afferents. The gastrointestinal stimulation also activates the axonal reflexes. The activation of the axonal reflexes is via the dichotomous branches of the spinal nerves. The electrical stimulation is administered concurrently with an endoscopic procedure or immediately following an endoscopic procedure. Also, provided herein is a method of preventing inflammation of a visceral organ comprising positioning a stimulatory electrode in proximity of descending efferents in the vagus, innervating the visceral organ, of an individual in need thereof, and administering repetitive trains of short pulse electrical stimulation effective in activating nicotinic receptors. | 01-20-2011 |
20110066208 | ILEAL ELECTRICAL STIMULATION - The disclosure is a method of treatment for obesity, in an individual in need thereof comprising positioning stimulatory electrodes in the distal small intestines or ileum, and administering electrical stimulation in trains of pulses or repetitive pulses, where the electrical stimulation is effective, at least in part in, stimulating the vagal afferent and efferent activity, of the distal small intestines or ileum, in the individual. The stimulation of the vagal afferent and efferent activity leads to the regulation of the ileal brake. Specifically, the electrical stimulation is provided in trains of pulses. Also, described is a method of treatment for functional gastrointestinal disease by ileal electrical stimulation. Further this invention provides a method of treatment for an eating disorder comprising administering ileal electrical stimulation effective, at least in part, in stimulating the vagal and sympathetic pathways. The stimulatory electrodes are placed by laparoscopic, endoscopic or surgical means. | 03-17-2011 |
Patent application number | Description | Published |
20080312678 | Methods and Devices for Treating Obesity - Methods and devices for treating obesity. Pressure is applied to gastric walls in at least one segment of a stomach such that the pressure distends the gastric walls and induces satiety. A hollow capsule can be used to distend the gastric walls. Alternatively, a doughnut-shaped ring may be inflated to an amount sufficient to create intragastric tension and induce satiety. A c-ring including at least one balloon may be placed at a segment of the stomach, where the balloon inflates to a size that creates tension at the segment. A biocompatible material can be injected into the fundus and antrum of the stomach to stiffen the gastric wall to create a fullness feeling. | 12-18-2008 |
20110028833 | METHODS AND APPARATUSES FOR ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY - A method is disclosed for distending a body lumen in the performance of endoscopic retrograde cholangiopancreatography (ERCP). The method comprises insufflating the body lumen with contrast agent to distend the body lumen. The contrast agent includes gas. | 02-03-2011 |
20110034967 | GASTROINTESTINAL ELECTRICAL STIMULATION - The disclosure provides a method of treatment for obesity, in an individual in need thereof, by administering electrical stimulation at dual sites in the gastrointestinal tract. The electrical stimulations are administered by positioning bipolar stimulatory electrodes in contact with the gastric and dudenol cavities, along afferent vagal neural pathways, in the gastrointestinal tract. The electrical stimulations thus administered, activate the vagal afferents associated with the gastric and dudenol sites in the gastrointestinal tract. The activation of vagal afferents modulates the gastrointestinal peptide satiety hormones. Further, the disclosure provides a method of treatment for eating disorders, in an individual in need thereof, by administering electrical stimulation at dual sites, along afferent vagal neural pathways, in the gastrointestinal tract. Also, provided is a method of regulating the appetite of an individual in need thereof, by administering electrical stimulation at dual sites in the gastrointestinal tract. | 02-10-2011 |
20110118812 | HEPATIC ELECTRICAL STIMULATION - The present invention relates to a method of providing electrical stimulation to a liver of a subject which includes providing one or more stimulatory electrodes to the liver of the subject and providing electrical stimulation to the liver of the subject. The invention further relates to methods of reducing risk factors of metabolic syndrome, treating diabetes, treating a subject having eating disorders and reducing glucose levels of a subject using methods of the present invention. | 05-19-2011 |
20110224491 | DEVICE AND METHOD FOR DEPLOYING CAP ON ENDOSCOPE - A system is disclosed for assisting in endoscopic procedures. The method comprises a cap and a device for deploying a cap on the endoscope while the endoscope is positioned within a body lumen. A method of deploying a cap on an endoscope during an endoscopic procedure is disclosed. The method comprises providing a cap and a device for deploying the cap on the endoscope while the endoscope is positioned with a body lumen, advancing the endoscopic within a body lumen and deploying the cap on the endoscope. | 09-15-2011 |
20120022322 | Methods and Devices for Treating Obesity - Methods and devices for treating obesity. Pressure is applied to gastric walls in at least one segment of a stomach such that the pressure distends the gastric walls and induces satiety. A hollow capsule can be used to distend the gastric walls. Alternatively, a doughnut- shaped ring may be inflated to an amount sufficient to create intragastric tension and induce satiety. A c-ring including at least one balloon may be placed at a segment of the stomach, where the balloon inflates to a size that creates tension at the segment. A biocompatible material can be injected into the fundus and antrum of the stomach to stiffen the gastric wall to create a fullness feeling. | 01-26-2012 |
20120071867 | DIODE LASER SYSTEMS AND METHODS FOR ENDOSCOPIC TREATMENT OF TISSUE - Embodiments of the present invention provide improved laser systems and methods for endoscopic laser treatment of abnormal tissue such as abnormal mucosal tissue, for example esophageal dysplasia that is also referred to as Barrett's esophagus (BE). The systems and methods described here can also be used in many applications where treatment of shallow surface layers with minimal damage to the tissue beneath is desirable, for example BE tissue comprising hemoglobin. In many embodiments, the system is configured to emit light energy having an optical wavelength to treat tissue having oxygenated hemoglobin. | 03-22-2012 |
20120164139 | Dopamine 3 receptor agonist and antagonist treatment of gastrointestinal motility disorders - Provided herein are methods of treating gastrointestinal motility disorders by targeting the dopamine 3 receptor (D3R). A D3R agonist is administered to a subject to decrease gastrointestinal motility to treat the disorder. A D3R antagonist is administered to a subject to decrease gastrointestinal motility to treat the disorder. | 06-28-2012 |
20140134167 | Transforming growth factor-beta (TGF-beta) antagonists for use in treating pain - Provided herein are methods for treating pain and for reducing the excitability of nociceptors, comprising administering a TGF-β antagonist. In some embodiments, a TGF-β antagonist is a monoclonal TGF-f3 neutralizing antibody or a fusion product comprising a monoclonal TGF-β neutralizing antibody, a soluble receptor, an antisense oligodeoxynucleotides (ODNs), a ribozymes, a small inhibitory RNA (siRNA), Smad 6, Smad7, or a small molecule that blocks TGF-β signaling. | 05-15-2014 |